ASCO 2022

Transatlantic differences in ADC side effects management

More data needed: Are the results clinical meaningful? How can SG fit in the therapy algorithm?

Paradigm shift in breast cancer: Where do we use the treatment option? How do we test HER2 status? How can we manage toxicity?

What are the cosenquences of the new OS data for CDK4/6 inhibitor therapy?

CDK4/6i switch: who benefits from switching the CDK4/6 inhibitor?

How to determine progress of disease? How to proceed therapy after CDK4/6i inhibitor? When should we change the endocrine combination partner?

Determining HER2 receptor expression: How do we target the HER2-low subtype?

Patients perspectives: ADCs - how do manage the new, smart chemotherapies?

ADCs & CDK4/6i - paradigm shifts and therapy switches in metastatic breast cancer

What clincial value has statistical signifcance? How can we improve trial design to become statistical and clinical significant?

Possible explanations of the negative study

Impressive and practice changing data of ADCs mark the beginning of a long success story

First evidence on benefit of CDK4/6 inhibitors beyond progression

SG is a new therapy option for HR+/HER2- MBC patients

No changes in clinical practice after new CDK4/6i-data

Endocrine therapy alone is important in treatment of elderly patients

Patritumab Deruxtecan: HER3-targeted ADC in HER3 -expressing mBC

Additional administration of ribociclib improves PFS after prior CDK4/6i therapy.

No effect for local treatment of metastasis

Combi SERD + Palbo reduces proliferation better than SERD + anastrozole

Sacituzumab govitecan improves PCr in patients with localized TNBC

Breakthrough news with antibody drug conjugate

Benefit of CDK4/6 Switch after Progression

Combination of ctDNA and TKa assesment may improve outcome prediction of RIB+LET treatment

Disappoiting final OS data and its implications for our patients

Exciting advances across a wide subset of breast cancers

Practice changing data

Fascinating data of ADCs in breast cancer at ASCO22

Good therapeutic option in HR+ HER2- mBC after failure of endocrine therapy

Revolution in the field of HR+ disease

Gamechanger in breast cancer

Palbociclib - Overall survival data

Exciting and practice changing news for HR+/Her2low MBC patients

ADC: future therapeutic option in advanced HR+/HER2 BC

Discontiunation of trial is disappointing despite negative results

Smart chemotherapy improves PFS

My ASCO22 highlights in metastatic breast cancer

Improvment of PFS & OS with activated alteration PIK3CA/AKT1/PTEN pathway.

New SoC for large subpopulation of breast cancer patients

T-DxD should be the new SoC for Her2low MBC patients

New standard of care for HR+/Her2low patients

Option for overcoming endocrine resistance?

Oligometastasis: no advantage of additional radiotherapy

SG may be a good option for pre-treated HR+/Her2- pts

New agents for the clincial practice

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Noutăți inovatoare cu conjugatul de medicamente cu anticorpi

SG come nuova opzione di cura per le pazienti con tumore mammario metastatico HR+/HER2-

Una rivoluzione per il tumore mammario endocrino-responsivo ed HER2 low

Novità entusiasmanti e practice changing per le pazienti con tumore mammario metastatico HR+/Her2low

I nuovi impressionanti risultati degli ADC a l’ASCO 2022 : l’inizio di una lunga storia di successi.

Il sacituzumab govitecan migliora il PFS nei tumori endocrino-responsivi

ADCs en cáncer de mama con receptores hormonales positivos

Nowy standard dla znaczącej subopulacji chorych na raka piersi

Les nouvelles données impressionnantes des ADC à l’ASCO 2022 : le début d'une longue histoire de succès

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po progresji

La valutazione combinata di ctDNA e TKa può aiutare a migliorare la selezione delle pazienti trattate con RIB+LET

CT benefit for elderly patients, if they are able to complete therapy.

Ovarian function suppression - it is here to stay!

Adding towards deescalation in luminal A EBC by omitting radiotherapy

Neoadjuvant Pembro decreased RCB. SG - first promising ADC in early TNBC!

Long term overall survival benefit of Denosumab in addition to improved bone health

High concordance of local, central IHC and RT-PCR for ER, PR and HER2

My ASCO22 highlights in early breast cancer

Combi SERD + Palbo redzuert proliferation better than SERD + anastrozole

Molecular landscape - Part 1

Immunotherapy - Part 1

Immunotherapy - Part 2

Molecular landscape - Part 2

COSMIC-021: Not practice-changing, but interesting results

CLN-081 is a promising new agent for EGFR exon 20 insertion NSCLC

New components and therapies for advanced NSCLC

New treatment options for METexon 14 skipping: amivantamab

In the second line: Options for Immunotherapy resistance and KRAS mutations

Multiple aquired resistance mutations may drive disease progression

Bispecific Antibodies - the cMET field is moving

Role of IO and chemo-IO in patients with PD-L1 > 50%

Promising results for pre-treated patients with KRASG12C mutation

KRASG12C mutation: Adagrasib is comparabale to sotorasib

Strategies for PD-L1 > 50%

CLN-081 for patients with metastatic NSCLC and an EGFRexon20 insertion

Is adagrasib an alternative to sotorasib?

A chemo-free option in patients with EGFR-mutation

New option in patients harboring METex14 mutation

Options after progression to chemo/IO and for KRASG12C mut

Amivantamab as a future option for METex14 patients?

PD-L1 over 50%: Chemo-IO or IO?

Veelbelovende resultaten voor voorbehandelde patienten met een KRAS G12C mutatie

CLN-081 voor patienten met gemetastaseerd NSCLC en een EGFRexon20 insertie

Segunda Linea: opciones tras resistencia a inmunoterapia y mutaciones de KRAS

Une nouvelle option, l’amivantamab, en situation de délétion dans l’exon 14 de MET

Was tun nach Versagen einer Chemoimmun-Therapie?

COSMIC-021: Nicht praxisverändernd, aber interessante Resultate

Bispezifische Antikörper - Neues von CHRYSALIS

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 > 50%

L’adagrasib, inhibiteur de la mutation KRASG12C: une efficacité comparable à celle du sotorasib?

PD-L1 über 50 % - was tun?

Nuevas terapias para el CPCNP avanzado

Nieuwe behandelopties voor METexon 14 skipping: amivantamab

Neoadjuvant and adjuvant therapy - Part 2

Neoadjuvant and adjuvant therapy - Part 1

NADIM-II strengthens the findings from CheckMate-816

Perspectives on multimodality

CheckMate-816: Neoadjuvant therapy

New treatment approaches in Stage III

A new option in neoadjuvant chemoimmunotherapy

Chimiothérapie néoadjuvante des stades III , vers un nouveau standard de soins

Neue Ansätze im Stadium III

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is here to stay

No benefit for tiragolumab / novel anti-PD-1 mAB serplulimab effective

SKYSCRAPER-02: Subgroups could be important

Immuncheckpoint-inhibitor therapy

Le Tiragolumab n’apporte pas de bénéfice à la chimioimmunothérapie de première ligne/ Une nouvelle phase III en faveur de la chimio immunothérapie de première ligne

mCRPC: LuPSMA - new treatment option in mCRPC

PARP inhibitors in mCRPC: Do we need more genetic testing?

mHSPC: Transatlantic differences in genetic testing & updates in doublets vs. triplets

Phase 1 study on combining LuPSMA treatment with immunotherapy

TheraP shows no difference in overall survival between cabazitaxel and LuPSMA

Lu-PSMA in the third line

SUV mean at PET images as a prognostic tool for PSMA treatment

GGT impacts PCa patients care

Ongoing trial invetiagting the impact of Bavdegalutamide on Arbiraterone restistance in pts with PCa

SUVmean is highly predictive of better PFS and OS

No big scoop, but encouraging results

Further updates from the VISION trial

The efficacy of doublets in mHSPC

Value of triple-therapy - complimentary study to ARASENS trial

3 year overall survival of TheraP study

Arbiraterone + Olaparib: Is it synergistic?

Surrogate endpoints in mHSPC

Lu-PSMA effective regardless of prior or concomitant therapy

Frequent imaging for early detection of metastases in nmCRPC.

SHR3680 - do we need a new androgen receptor inhibitor

PFS good surrogate endpoint for overall survival

ADT alone is no longer standard of care

LuPSMA & cabazitaxel are better than SoC alone

The highlights in GU cancers of ASCO22

Pas de nouvelles sensationnelles mais des données encourageantes

Lo mas destacado en tumores GU en ASCO 2022

Treårs överlevnadsresultat i TheraP studien.

Tidigare endpoints I mHSPC studier

Kvantifiering av PMSA PET upptaget som prognostisk markör i VISION studien

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas 1 prövning

What are the consequences for future trial design?

The relevance of quality of life in kidney cancer!

EVEREST: Inisghts from the negative trial

Combination Therapy is State of the Art in Metastatic Renal Cell Carcinoma.

QoL & DepOR correlate with clinical outcomes - reminder for future trial designs

Depth of remission in firstline

The highlights in GU cancers of ASCO22

Should Everolimus be revisited for high-risk patients?

Belzutifann shows good tumor activity in renal cancer

PSMA-PET may improve imaging of clear cell RCC

Clear evidence for durable benefit for patients with von Hippel-Lindau disesase

Importance of health related quality of life

Should we be looking at Everolimus in the future?

Combi Axi + Pembro also successful with good risk profile

Lo mas destacado en tumores GU en ASCO 2022

Pas de nouvelles sensationnelles mais des données encourageantes

ADCs: do we enter a new era of therapy for urothelial cancer?

New data on TKi utilization in bladder cancer

The role of systemic treatment in the pre-operative setting and updates on Avelumab maintenance

ADCs: News from ASCO 2022

The end of of VEGF-targeted therapy in urothelial cancer?

BCG failure

No big scoop, but encouraging results

The highlights in GU cancers of ASCO22

My highlights in localized urothelial cancer

Maintenance concepts

Investigating sasanlimab in BCG-unresponsive NMIBC

Exciting future for ADCs

Perioperative immuno-chemotherapy in MIBC

My highlights of metastasized urothelial cancer

Lo mas destacado en tumores GU en ASCO 2022

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το ASCO 2022

Radiotherapy as a new standard for cisplatin ineligible patients

Systemic therapy

News from Sarcoma

Opportunities & challenges of cancer genetics

Precision oncology - NTRK worth to search the patients

Few testicular tumors after 5 years